Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

Autor: M.A.F.J. van de Laar, J. Delsing, E.N. Van Roon, EN Griep, Miriam Hoekstra, Jrbj Brouwers, T.L.Th.A. Jansen, M.K. Reinders

Publikováno v: Annals of the Rheumatic Diseases, 68(1), 51-67. BMJ PUBLISHING GROUP
Annals of the rheumatic diseases, 68(1), 51-56. BMJ

Objectives:To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment.Methods:Prospective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbbfc9c96f05d6d2a1742abc878d427
https://research.rug.nl/en/publications/69863204-0925-4014-9f23-35c8e1518df6

FRI0012 Adverse events, drug withdrawal and efficacy of leflunomide in unselected outpatients with rheumatoid arthritis

Autor: L Mourad, PM Houtman, E.N. Van Roon, T.L. Jansen, WA Baars, G. A. W. Bruyn, EN Griep, Jacobus R. B. J. Brouwers

Publikováno v: Speaker abstracts 2001.

Background Objectives Leflunomide (LEF) is a disease modifying antirheumatic prodrug with immunomodulating, antiproliferative and antiinflammatory properties. We studied our first daily practice experience with LEF in the Outpatient Department of Rhe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a649931d6567408cd5b5e60f903d8fca
https://doi.org/10.1136/annrheumdis-2001.1141

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.

Autor: Boers M; Epidemiology & Data Science, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands eds@amsterdamumc.nl.; Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Hartman L; Epidemiology & Data Science, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.; Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Opris-Belinski D; Rheumatology, Carol Davila University of Medicine and Pharmacy, Romania, Bucharest, Romania., Bos R; Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., Kok MR; Rheumatology and Clinical Immunology, Maasstad Ziekenhuis, Rotterdam, The Netherlands., Da Silva JA; Reumatologia, Faculdade de Medicina e Hospitais da Universidade de Coimbra, Coimbra, Portugal., Griep EN; Rheumatology, Antonius Hospital, Sneek, The Netherlands., Klaasen R; Rheumatology, Meander Medisch Centrum, Amersfoort, The Netherlands., Allaart CF; Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Baudoin P; Rheumatology, Reumazorg Flevoland, Emmeloord, The Netherlands., Raterman HG; Rheumatology, Northwest Clinics, Alkmaar, The Netherlands., Szekanecz Z; Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Buttgereit F; Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany., Masaryk P; National Institute of Rheumatic Diseases, Piestany, Slovakia., Klausch LT; Epidemiology & Data Science, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Paolino S; Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy., Schilder AM; Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., Lems WF; Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands., Cutolo M; Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2022 Jul; Vol. 81 (7), pp. 925-936. Date of Electronic Publication: 2022 May 31.

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Autor: Verhoeven MMA; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Tekstra J; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Welsing PMJ; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Pethö-Schramm A; F. Hoffmann-La Roche, Basel, Switzerland., Borm MEA; Roche Nederland BV, Woerden., Bruyn GAW; Department of Rheumatology, MC Group, Lelystad., Bos R; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden., Griep EN; Department of Rheumatology, Antonius Hospital, Sneek., Klaasen R; Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands., van Laar JM; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Lafeber FPJG; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Bijlsma JWJ; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., de Hair MJH; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Jacobs JWG; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2020 Sep 01; Vol. 59 (9), pp. 2325-2333.

High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-α blocking therapy in ankylosing spondylitis.

Autor: Wink F; 1Rheumatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Arends S; Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Maas F; Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Bootsma H; Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Griep EN; Rheumatology, Antonius Hospital, Sneek, The Netherlands., Bruyn GAW; Rheumatology, MC Groep Hospitals, Lelystad, The Netherlands., Spoorenberg A; Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2019 Jun 01; Vol. 58 (6), pp. 1040-1046.